NPM1 and acute myeloid leukemia: NPM1 mutations may render AML patients susceptible to ATRA, raising the possibility that a strategy targeting mutant oncoproteins to selectively induce NPM1 mutated protein degradation, that involved ATRA, may be a feasible alternative to specific pharmacologic NPM1 inhibitors.